Det er en meget spændende og stor indikation indenfor NHL, hvor der som der står nedenfor ikke rigtigt er fundet en guld standard terapi for relapsed patienter. http://www.haematologica.org/cgi/content/full/93/12/1776

Man er oppe imod 2 med betydeligt lavere ORR i indikationen.

Conclusions

The treatment paradigm in patients with relapsed and refractory diffuse large B cell lymphoma is still being defined. Outcome after failure of R-CHOP induction chemotherapy continues to be dismal, and efforts to define patients with refractory disease and early relapse will be crucial. Autologous stem cell transplant following high-dose chemotherapy remains the standard of care but will need to be revisited in the post-rituximab era. Salvage therapy of choice and the role of rituximab remain to be elucidated, and the results from the CORAL study are eagerly anticipated. Novel targeted therapeutics are evolving, and further incorporation of these agents into induction or salvage treatments will be the key in future.